How Abbott’s Libre Duo Launch Could Impact the Continuous Glucose Monitoring (CGM) Market, Expected to Reach USD 19.4 Billion by 2031

In August 2026, the FDA authorized Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System, introducing a new wearable monitoring approach that combines continuous glucose and ketone measurements in one sensor. The authorization expands the role of wearable biosensing beyond glucose monitoring and adds continuous ketone visibility to diabetes management. The FDA states that Libre Duo is authorized for people aged 2 years and older living with diabetes and was reviewed through the De Novo pathway.

Libre Duo continuously measures glucose and ketones in the fluid beneath the skin every minute, transferring its readings wirelessly to a compatible smartphone. The system can provide alerts when ketone levels reach a concerning threshold, potentially allowing users and caregivers to identify rising ketone levels earlier. The FDA stated that the authorization was based on six clinical studies involving over 600 participants that evaluated the system's accuracy across various glucose and ketone levels.

The system continuously monitors glucose and ketone levels through a single wearable sensor, providing real-time readings, alarms, and trend information. By adding continuous ketone monitoring to established CGM functionality, Libre Duo broadens the role of wearable biosensors in diabetes management. The product could also influence competition as manufacturers explore multi-biomarker sensing, connected insulin delivery, and integrated digital health platforms.

Recent Developments in the Continuous Glucose Monitoring Market

• July 2026: Dexcom received Health Canada authorization for G7 15 Day, providing adults living with diabetes with a CGM system offering up to 15.5 days of wear.

• June 2026: MiniMed launched its Instinct and Instinct Go CGM sensors in Europe, expanding its next-generation continuous glucose monitoring footprint with advanced design attributes crafted to optimize patient comfort and daily wearability.

• June 2026: Dexcom announced developments around its Stelo glucose biosensor, including a redesigned app experience and pediatric clearance, while also highlighting expansion of glucose biosensing into earlier-stage intervention and preventative health applications.

How This Reshapes Continuous Glucose Monitoring Competition

Abbott’s Libre Duo could intensify competition in the CGM market by expanding product differentiation beyond continuous glucose measurement toward multi-biomarker monitoring. Its ability to continuously track both glucose and ketones introduces an additional layer of physiological insight for diabetes management. The development may encourage competitors such as Dexcom and Medtronic to explore broader biomarker monitoring, longer sensor wear, and deeper integration with digital health platforms. Meanwhile, connected applications, real-time alerts, remote data sharing, and integration with insulin-delivery systems are becoming increasingly important competitive factors. As CGM technology evolves, manufacturers may increasingly compete on monitoring capabilities, convenience, personalization, and ecosystem integration.

How Knowledge Sourcing Intelligence's (KSI) Continuous Glucose Monitoring Market Report Can Help

Knowledge Sourcing Intelligence's Continuous Glucose Monitoring Market report provides a structured market perspective, where companies can see how their launches fit into the category-level demand.

The report examines the CGM market across applications including diabetes patients and critical-care patients, as well as end-user segments such as hospitals, diagnostic centers and clinics, and home care. This segmentation can help stakeholders evaluate the potential implications of emerging technologies such as Abbott’s dual glucose-ketone monitoring system and assess opportunities across clinical and home-based monitoring environments.

Request a free sample copy or view the report summary: Continuous Glucose Monitoring (CGM) Market Report

Continuous Glucose Monitoring Market Report Highlights

• Wearable sensor technology is enabling continuous, real-time glucose monitoring and increasingly integrating with broader digital health platforms.

• Longer sensor wear periods are becoming an important area of product development, as demonstrated by products such as Dexcom G7 15 Day.

• Multi-biomarker monitoring represents an emerging development, with Libre Duo combining continuous glucose and ketone sensing in one wearable system.

• Integration with insulin delivery, mobile applications, remote monitoring, and personalized health insights is expanding the role of CGM technology beyond standalone glucose measurement.

Continuous Glucose Monitoring Market Growth Drivers and Restraints

Growth Drivers:

• Growing Prevalence of Diabetes: The increasing number of people living with diabetes is supporting demand for continuous monitoring technologies. The FDA estimates that approximately 40.1 million Americans are living with diabetes.

• Expansion of Wearable Monitoring: Smaller and more convenient wearable sensors are supporting broader adoption of continuous glucose monitoring across home and clinical settings.

• Integration with Digital Health Platforms: CGM data can increasingly be connected with smartphone applications, insulin-delivery systems, smart pens, caregivers, and healthcare providers.

• Multi-Biomarker Monitoring: Abbott’s Libre Duo demonstrates how CGM technology can evolve toward simultaneous monitoring of glucose and other physiological biomarkers, potentially expanding the functionality of wearable diabetes devices.

• Longer Sensor Wear: Products offering extended wear periods can reduce the frequency of sensor replacement and improve convenience for users. Dexcom’s G7 15 Day, for example, offers up to 15.5 days of wear for authorized adult users in Canada.

Restraints:

• Accuracy and Clinical Requirements: CGM devices must maintain reliable performance across different glucose and physiological conditions, while expanded monitoring capabilities require additional clinical and regulatory validation.

• Cost and Reimbursement: Sensor costs, insurance coverage, and reimbursement policies can influence adoption, particularly among users who require long-term monitoring.

• Data Privacy and Security: Continuous monitoring generates substantial health data, increasing the importance of secure data transmission, storage, and responsible use.

• User Adherence and Wearability: Skin irritation, sensor placement, replacement requirements, and long-term comfort remain important considerations for wearable CGM adoption.

• Regulatory Complexity: Expansion from glucose monitoring into additional biomarkers introduces new performance, labeling, and regulatory considerations, as illustrated by the FDA’s De Novo authorization and special controls established for Libre Duo.

Market Segmentation

Continuous Glucose Monitoring Market Key Players

• Abbott Laboratories 

• DexCom, Inc. 

• Medtronic Plc 

• F. Hoffmann-La Roche AG 

• Senseonics Holdings, Inc.